Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 19.45 4.29% 0.80
ACOR closed up 4.29 percent on Friday, June 23, 2017, on 1.38 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ACOR trend table...

Date Alert Name Type % Chg
Jun 23 Expansion Breakout Bullish Swing Setup 0.00%
Jun 23 180 Bullish Setup Bullish Swing Setup 0.00%
Jun 15 NR7 Range Contraction 13.74%
Jun 15 NR7-2 Range Contraction 13.74%
Jun 15 Upper Bollinger Band Walk Other 13.74%

Older signals for ACOR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 33.0
52 Week Low 13.6
Average Volume 957,901
200-Day Moving Average 20.4847
50-Day Moving Average 16.096
20-Day Moving Average 16.485
10-Day Moving Average 17.865
Average True Range 0.7886
ADX 38.86
+DI 39.67
-DI: 10.42
Chandelier Exit (Long, 3 ATRs) 17.2342
Chandelier Exit (Short, 3 ATRs) 15.9658
Upper Bollinger Band 19.7262
Lower Bollinger Band 13.2438
Percent B (%b) 0.96
Bandwidth 0.39323
MACD Line 0.7561
MACD Signal Line 0.3717
MACD Histogram 0.3844